

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2013-11-12T03:23:59Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:srpt="http://www.sareptatherapeutics.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="srpt-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="eol_PE3458----1310-Q0009_STD_0_20130228_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_2001_0">7300000</us-gaap:LettersOfCreditOutstandingAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20131031_0" unitRef="shares" decimals="INF" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_2_5">37582309</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:TenantImprovements contextRef="eol_PE3458----1310-Q0009_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_2005_16">3700000</us-gaap:TenantImprovements>
  <srpt:WarrantsValuation contextRef="eol_PE3458----1310-Q0009_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C239D094-8F70-4C47-BE2F-423175BE7831_4001_0">79116000</srpt:WarrantsValuation>
  <srpt:PropertyPlantAndEquipmentIncludingConstructionInProgress contextRef="eol_PE3458----1310-Q0009_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_2005_15">4700000</srpt:PropertyPlantAndEquipmentIncludingConstructionInProgress>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3458----1310-Q0009_STD_0_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3002_31">37987000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_36">37533695</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_32" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_3001_8">891157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_3001_6">23.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_3001_6">4150834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_29">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_31" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_3001_7">21.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_3001_9">47.23</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_3001_8">11.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_35">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_34">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2003_3">959283</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_30">3333333</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_3001_7">3395249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_37">37533695</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_26" />
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_18">91000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_22">51101000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_19">35994000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_17">2909000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_23">1599000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_9">17345000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_38">781396000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_16">8129000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RestructuringReserve contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C269DCE9-4D69-402D-BA05-0D774575A8EF_1001_4">90000</us-gaap:RestructuringReserve>
  <us-gaap:StockholdersEquity contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_40">246984000</us-gaap:StockholdersEquity>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_20">3963000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_28" />
  <us-gaap:Liabilities contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_25">57495000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_24">4795000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_21">15000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_11">1538000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_33">4000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_41">304479000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_12">25000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_3">6721000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_00CED321-5D08-4346-BF56-B4460AA4BF2F_1001_1">4200000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_8">8244000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_13">304479000</us-gaap:Assets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2548261_F4759D43-9063-4F42-BFF1-8612713E0C00_1001_3">88063000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_2">273644000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_10">5231000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_2548261_F4759D43-9063-4F42-BFF1-8612713E0C00_1001_4">31748000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_39">534416000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2548261_F4759D43-9063-4F42-BFF1-8612713E0C00_1001_2">99056000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:RestrictedCashAndInvestments contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_CF4BDF44-36C2-4052-A0DD-79ADA194FCAB_1_2">7800000</us-gaap:RestrictedCashAndInvestments>
  <us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_4">7250000</us-gaap:RestrictedCashAndInvestmentsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_5">2807000</us-gaap:OtherAssetsCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_5FFCF34E-A4E1-48E9-B818-81F19416555A_1_0">49600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_CF4BDF44-36C2-4052-A0DD-79ADA194FCAB_1_0">281400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_7">557000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_1_6">290422000</us-gaap:AssetsCurrent>
  <srpt:ClassOfWarrantOrRightExercisable contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2003_6">959283</srpt:ClassOfWarrantOrRightExercisable>
  <srpt:CertificatesOfDepositMaturityDate contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_2_2">2014-04</srpt:CertificatesOfDepositMaturityDate>
  <srpt:WarrantsValuation contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C239D094-8F70-4C47-BE2F-423175BE7831_2001_3">35994000</srpt:WarrantsValuation>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2002_2">10.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2002_3">727180</us-gaap:ClassOfWarrantOrRightOutstanding>
  <srpt:ClassOfWarrantOrRightExercisable contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2002_6">727180</srpt:ClassOfWarrantOrRightExercisable>
  <srpt:WarrantExpirationDate contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2002_4">2014-08-31</srpt:WarrantExpirationDate>
  <srpt:WarrantIssueDate contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2002_1">2009-08-25</srpt:WarrantIssueDate>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399" unitRef="iso4217_USD_per_Right" decimals="2" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2001_2">6.96</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2001_3">232103</us-gaap:ClassOfWarrantOrRightOutstanding>
  <srpt:ClassOfWarrantOrRightExercisable contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399" unitRef="shares" decimals="INF" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2001_6">232103</srpt:ClassOfWarrantOrRightExercisable>
  <srpt:WarrantExpirationDate contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2001_4">2014-07-30</srpt:WarrantExpirationDate>
  <srpt:WarrantIssueDate contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2001_1">2009-01-30</srpt:WarrantIssueDate>
  <srpt:PeriodOfPerformanceSpanning contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_711809x804211" id="id_2548261_7202B35D-4EBE-4FF5-9CB5-7B1B836038B0_2001_1">P4Y</srpt:PeriodOfPerformanceSpanning>
  <srpt:EstimatedFunding contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_711809x828901" unitRef="iso4217_USD" decimals="-5" id="id_2548261_C18AFF26-4357-4AE2-98D6-A8AF3B53ECFD_1001_0">84400000</srpt:EstimatedFunding>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3001_1">35994000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3001_2">35994000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_2001_3">7807000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3002_1" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3002_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_2002_3">7807000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740_715990x708500" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_3002_2">557000</us-gaap:RestrictedInvestmentsAtFairValue>
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740_715990x715868" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_4002_1">7250000</us-gaap:RestrictedInvestmentsAtFairValue>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3003_1" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3003_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_2003_3" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855_715990x708500" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_3003_2" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_4003_1" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3004_1">35994000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3004_2">35994000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_2004_3" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798_715990x708500" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_3004_2" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_4004_1" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715990x708500" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_3001_2">557000</us-gaap:RestrictedInvestmentsAtFairValue>
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715990x715868" unitRef="iso4217_USD" decimals="-3" id="id_2548261_2B637AEE-5101-4A3D-B98A-DA9F27BDA763_4001_1">7250000</us-gaap:RestrictedInvestmentsAtFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715677" unitRef="shares" decimals="INF" id="id_2548261_4D373CC7-FBB0-4422-9EEE-1B317DAD0299_2001_1">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715677_713879x837386" unitRef="shares" decimals="INF" id="id_2548261_4D373CC7-FBB0-4422-9EEE-1B317DAD0299_3001_2">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715834" unitRef="shares" decimals="INF" id="id_2548261_6583C58E-E609-4835-A63B-0E0436042718_2001_4">13028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715834" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_412297E6-BA2F-402C-ACDD-C9368B316898_2001_4">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_683B19F3-31F3-4366-AF72-D944C2A1E995_2001_4">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_0226406A-AF0D-4E45-BD54-BB8592E5FC44_2001_4">34.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_713879x837386" unitRef="shares" decimals="INF" id="id_2548261_4D373CC7-FBB0-4422-9EEE-1B317DAD0299_4001_0">2950714</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_7">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_5">600000</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_10">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_8">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_11">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_9">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <srpt:OperatingLeasesFutureMinimumPaymentsDueInSixYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_12">2400000</srpt:OperatingLeasesFutureMinimumPaymentsDueInSixYears>
  <srpt:OperatingLeasesFutureMinimumPaymentsDueInSevenYears contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1002_13">2400000</srpt:OperatingLeasesFutureMinimumPaymentsDueInSevenYears>
  <us-gaap:DeferredRevenue contextRef="eol_PE3458----1310-Q0009_STD_0_20130930_0_716644x708634" unitRef="iso4217_USD" decimals="-5" id="id_2548261_4702E91D-49E2-46EF-A6CA-DB1F9F85FE27_2001_2">700000</us-gaap:DeferredRevenue>
  <us-gaap:SharePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_4001_8">4.50</us-gaap:SharePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3458----1310-Q0009_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_5001_30">39904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_36">31703817</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_32" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_1001_2">11.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_1001_2">2522522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_29">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_31" />
  <us-gaap:SharePrice contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_3002_8">25.80</us-gaap:SharePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_35">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_34">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_30">3333333</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_37">31703817</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_26" />
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_18">89000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_22">78886000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_19">65193000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_17">2741000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_23">1668000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_9">16708000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_38">554927000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_16">7532000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RestructuringReserve contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C269DCE9-4D69-402D-BA05-0D774575A8EF_2001_1">185000</us-gaap:RestructuringReserve>
  <us-gaap:StockholdersEquity contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_40">123679000</us-gaap:StockholdersEquity>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_20">3304000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_28" />
  <us-gaap:Liabilities contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_25">81314000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_24">760000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_21">27000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_11">2626000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:CommonStockValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_33">3000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_41">204993000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_12">2775000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_3">4713000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_A988362E-4F03-4532-ACF9-57D5020D0ED6_1_0">114100000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_00CED321-5D08-4346-BF56-B4460AA4BF2F_2_1">3200000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_8">3397000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_13">204993000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_2">187661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_10">4913000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_39">431251000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_5">1534000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E5071092-E726-44A6-AC54-942035798460_2_6">193908000</us-gaap:AssetsCurrent>
  <srpt:WarrantsValuation contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C239D094-8F70-4C47-BE2F-423175BE7831_3001_0">65193000</srpt:WarrantsValuation>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1001_3">65193000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1001_4">65193000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_2001_2" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1002_3" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1002_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_2002_2" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_3002_1" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1003_3" />
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1003_4" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_2003_2" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_3003_1" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1004_3">65193000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1004_4">65193000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_2004_2" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_3004_1" />
  <us-gaap:RestrictedInvestmentsAtFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715990x715868" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_773F5518-FD43-4664-A83E-4284CEA74ABA_3001_1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x715834" unitRef="shares" decimals="INF" id="id_2548261_6583C58E-E609-4835-A63B-0E0436042718_3001_0">38260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x715834" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_412297E6-BA2F-402C-ACDD-C9368B316898_3001_0">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_683B19F3-31F3-4366-AF72-D944C2A1E995_3001_0">4998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_0226406A-AF0D-4E45-BD54-BB8592E5FC44_3001_0">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_14">-306781000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_17">21749000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_16">13138000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_16">7807000</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_19">112993000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_21">2389000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_4">-3096000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_25">497000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:InterestPaid contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_33">698000</us-gaap:InterestPaid>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_7">9804000</us-gaap:InvestmentIncomeNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_12">9281000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
  <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_14">-17001000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_18">-534416000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_0">185141000</us-gaap:ContractsRevenue>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_15">3863000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_5">-418103000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_18">11810000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsForTenantImprovements contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_37">3692000</us-gaap:PaymentsForTenantImprovements>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_11">-116313000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_12">-534416000</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_26">-564000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_3">140282000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_27">619449000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_8">39549000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_28">273644000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_13">14280000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:ImpairmentOfRealEstate contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_7">1445000</us-gaap:ImpairmentOfRealEstate>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_3">22968000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_4">29461000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ImpairmentOfInvestments contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_10">17001000</us-gaap:ImpairmentOfInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_20">117724000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_22">-39024000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_2">433501000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_5_8">112979000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_24">620510000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <srpt:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_35">17897000</srpt:ShortTermSecuritiesAvailableForSaleReceivedInConnectionWithPrivateOffering>
  <srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_3_36">108044000</srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <us-gaap:StockIssued1 contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x709525" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1003_40">8075000</us-gaap:StockIssued1>
  <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x709525" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1003_41">2124000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
  <us-gaap:StockIssued1 contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x715869" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2003_38">750000</us-gaap:StockIssued1>
  <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x715869" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2003_39">2200000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
  <dei:TradingSymbol contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_1_0">SRPT</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_1_1">Sarepta Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_ED870B02-C252-40C0-BF9B-DE66EE760D59_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_1_4">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_ED870B02-C252-40C0-BF9B-DE66EE760D59_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_ED870B02-C252-40C0-BF9B-DE66EE760D59_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_ED870B02-C252-40C0-BF9B-DE66EE760D59_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_1_2">0000873303</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_066DD104-F62E-400F-8486-8BC38294194E_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_ED870B02-C252-40C0-BF9B-DE66EE760D59_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_19">-3.17</us-gaap:EarningsPerShareBasic>
  <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_96EDF6CF-DE9E-494E-9E62-35D5C9FC5649_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table sets forth the revenue for each of the
 Company&amp;#x2019;s contracts with the U.S. and E.U. governments and
 other revenue for the three and nine months ended
 September&amp;#xA0;30, 2013 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 July 2010 Contract &lt;i&gt;(Ebola and Marburg IV)&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,511&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 August 2012 Contract &lt;i&gt;(Intramuscular&lt;/i&gt;)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 November 2012 EU-SKIP-NMD Agreement &lt;i&gt;(DMD)&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 July 2013 Children&amp;#x2019;s National Medical Center&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Other Agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,593&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_69029785-E5CA-4A10-A7E0-F1F0B6D765F5_2001_2">P8Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_294F0A6C-0691-41C7-A72A-0F0BCC692E2E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;4. ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts receivable are generally stated at invoiced amount and do
 not bear interest. Because the accounts receivable are primarily
 from the DoD and historically no amounts have been written off, an
 allowance for doubtful accounts receivable is not considered
 necessary. The accounts receivable balance included $4.2 million
 and $3.2 million of DoD receivables that were unbilled at
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_5001_3">2063396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_20">-3.17</us-gaap:EarningsPerShareDiluted>
  <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_0E37E176-1199-4305-B9DB-AEE78D33C802_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Changes in the liability and the balance related to the
 restructuring plan are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="18%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ending&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restructuring charges&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(821&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_AB1A40EE-81B5-4CD5-87A7-B715FE3FD4C2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of the Company&amp;#x2019;s stock option activity with respect
 to the nine months ended September&amp;#xA0;30, 2013 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.15pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,522,522&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,063,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(196,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(239,072&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,150,834&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99,056,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Vested at September&amp;#xA0;30, 2013 and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,395,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,063,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Exercisable at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;891,157&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,748,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_90EF1850-0869-40C4-BAF4-C143BC93FD47_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;3. FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company measures at fair value certain financial assets and
 liabilities in accordance with a hierarchy of valuation techniques
 based on whether the inputs to those valuation techniques are
 observable or unobservable. Observable inputs reflect market data
 obtained from independent sources, while unobservable inputs
 reflect the Company&amp;#x2019;s market assumptions. There are three
 levels of inputs that may be used to measure fair-value:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1 &amp;#x2014; quoted prices for
 identical instruments in active markets;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2 &amp;#x2014; quoted prices for
 similar instruments in active markets, quoted prices for identical
 or similar instruments in markets that are not active, and
 model-derived valuations in which all significant inputs and
 significant value drivers are observable in active markets;
 and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="3%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3 &amp;#x2014; valuations derived
 from valuation techniques in which one or more significant value
 drivers are unobservable.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s assets and liabilities measured at fair value
 on a recurring basis consisted of the following as of the date
 indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments, current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments, noncurrent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;557&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;557&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,807&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,807&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;See Note 5 for additional information
 related to the determination of fair value of warrants and a
 reconciliation of changes in fair value.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The carrying amounts reported in the unaudited condensed
 consolidated balance sheets for cash and cash equivalents, accounts
 receivable, and accounts payable approximate fair value because of
 the immediate or short-term maturity of these financial instruments
 and carrying amounts reported for long-term debt approximate fair
 value based on market activity for other debt instruments with
 similar characteristics and comparable risk&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_D07B1432-FC2E-4969-BFF3-8186B1A03123_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table summarizes the outstanding warrants at
 September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="45%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 35.3pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;b&gt;Issue Date&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Outstanding&amp;#xA0;Warrants&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;at September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual Life&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 1/30/2009&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;232,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7/30/2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;232,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 8/25/2009&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8/31/2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;!-- xbrl,n --&gt;
 
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_445E156E-EC67-4759-8817-D9CB3655AACE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s assets and liabilities measured at fair value
 on a recurring basis consisted of the following as of the date
 indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments, current&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments, noncurrent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;557&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;557&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,807&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;7,807&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurement&amp;#xA0;as&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;See Note 5 for additional information
 related to the determination of fair value of warrants and a
 reconciliation of changes in fair value.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_5001_3">34.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_AD4C3A3E-5103-47FD-8071-D31839A44ADE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A reconciliation of the change in value of the Company&amp;#x2019;s
 warrants recorded as liabilities for the three and nine months
 ended September&amp;#xA0;30, 2013 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine months&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Increase in value of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Reclassification to stockholders&amp;#x2019; equity upon exercise of
 warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(60,282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(75,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_14CF787C-C4A0-4309-AAF8-74595FE93FAC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;5. WARRANTS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has periodically issued warrants in connection with
 certain common stock offerings. The warrants issued in
 January&amp;#xA0;and August&amp;#xA0;2009 are classified as liabilities as
 opposed to equity because their settlement terms require settlement
 in registered shares, which is outside of the Company&amp;#x2019;s
 control. These warrants are non-cash liabilities and the Company is
 not required to expend any cash to settle these liabilities. All
 other warrants issued by the Company were recorded as additional
 paid-in-capital and no further adjustments are made.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The outstanding warrants classified as liabilities are recorded at
 fair value on the condensed consolidated balance sheet and are
 adjusted to fair value at each financial reporting period, with
 changes in the fair value being recorded as &amp;#x201C;Loss on change
 in warrant valuation&amp;#x201D; in the condensed consolidated statement
 of operations and comprehensive income (loss). The fair value is
 determined using the Black-Scholes-Merton option-pricing model,
 which requires the use of significant judgment and estimates for
 the inputs used in the model. The following reflects the
 weighted-average assumptions for each of the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.2%-0.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8-0.9&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1-1.6&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility (1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;67.8%-72.7&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;139.2%-164.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Shares underlying warrants classified as liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,127,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Market value of stock at beginning of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Market value of stock at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47.23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;For the three and nine months ended
 September&amp;#xA0;30, 2013, expected volatility was estimated using a
 blend of calculated volatility of the Company&amp;#x2019;s common stock
 over a historical period and implied volatility in exchange-traded
 options associated with the Company&amp;#x2019;s common stock. Prior to
 January&amp;#xA0;1, 2013, expected volatility was estimated using
 calculated volatility of the Company&amp;#x2019;s common stock over a
 historical period commensurate with the expected term of the
 option.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A reconciliation of the change in value of the Company&amp;#x2019;s
 warrants recorded as liabilities for the three and nine months
 ended September&amp;#xA0;30, 2013 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine months&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;ended&lt;br /&gt;
 September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;79,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;65,193&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Increase in value of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Reclassification to stockholders&amp;#x2019; equity upon exercise of
 warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(60,282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(75,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the nine months ended September&amp;#xA0;30, 2013, 2,168,335
 warrants were exercised at a weighted average exercise price of
 $7.91, generating proceeds of $17.1 million. For the nine months
 ended September&amp;#xA0;30, 2012, 80,014 warrants were exercised at a
 weighted average exercise price of $4.08, generating proceeds of
 $0.3 million.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table summarizes the outstanding warrants at
 September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="45%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 35.3pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;b&gt;Issue Date&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Outstanding&amp;#xA0;Warrants&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;at September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Expiration&amp;#xA0;Date&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual Life&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 1/30/2009&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;232,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7/30/2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;232,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 8/25/2009&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8/31/2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;727,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="pure" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1_2">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="-5" id="id_2548261_B4E5FC05-CC7A-4F1B-AF01-BF98CBF856DF_2_0">3400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_9B55F4FD-1E38-4C43-A406-4FD486239E03_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;7. CONTRACT REVENUE&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognizes revenue from U.S. and European Union (E.U.)
 government research contracts during the period in which the
 related expenditures are incurred and presents revenue and related
 expenses gross in the condensed consolidated financial statements.
 In the periods presented, substantially all of the revenue
 generated by the Company was derived from government research
 contracts.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table sets forth the revenue for each of the
 Company&amp;#x2019;s contracts with the U.S. and E.U. governments and
 other revenue for the three and nine months ended
 September&amp;#xA0;30, 2013 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 July 2010 Contract &lt;i&gt;(Ebola and Marburg IV)&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,511&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 August 2012 Contract &lt;i&gt;(Intramuscular&lt;/i&gt;)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 November 2012 EU-SKIP-NMD Agreement &lt;i&gt;(DMD)&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 July 2013 Children&amp;#x2019;s National Medical Center&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Other Agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,593&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,993&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;U.S. Government Contracts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of September&amp;#xA0;30, 2013, the Company had completed all of its
 contracts with the DoD except for the Marburg portion of the July
 2010 contract for the development of therapeutics against Ebola and
 Marburg viruses.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;&lt;u&gt;July&amp;#xA0;2010 Contract (Ebola and Marburg Intravenous
 administration)&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On July&amp;#xA0;14, 2010, the Company was awarded a DoD contract
 managed by the Joint Project Manager Transformational Medical
 Technologies (JPM-TMT) Project Management Office, a component of
 the Joint Program Executive Office for Chemical and Biological
 Defense, for the advanced development of the Company&amp;#x2019;s
 hemorrhagic fever virus therapeutic candidates, AVI-6002 and
 AVI-6003,&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 against the Ebola and Marburg viruses, respectively. In February
 2012, the Company announced that it received permission from the
 U.S. Food and Drug Administration (FDA) to proceed with a single
 oligomer from AVI-6003, AVI-7288, as the lead product candidate
 against Marburg virus infection.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On August&amp;#xA0;2, 2012, the Company received a stop-work order
 related to the Ebola virus portion of the contract and, on
 October&amp;#xA0;2, 2012, the DoD terminated the Ebola portion of the
 contract for the convenience of the government due to government
 funding constraints.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The remaining Marburg portion of the contract is structured into
 four segments and has an aggregate remaining period of performance
 spanning approximately four years if the DoD exercises its options
 for all segments.&amp;#xA0;Activities under the first segment began in
 July 2010 and include Phase I studies in healthy volunteers as well
 as preclinical studies.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 After completion of the first segment, and each successive segment,
 the DoD has the option to proceed to the next segment. If the DoD
 exercises its options for segments II, III and IV, the
 Company&amp;#x2019;s contract activities would include all clinical and
 licensure activities necessary to obtain FDA regulatory approval
 for the therapeutic candidate against the Marburg virus. The
 funding for segments II, III and IV of the Marburg virus portion of
 the contract is estimated to be approximately $84.4 million.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;&lt;u&gt;August 2012 Contract (Intramuscular
 administration)&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On August&amp;#xA0;29, 2012, the Company was awarded a contract from
 the DoD, which is also managed by the JPM-TMT. The contract was
 awarded for approximately $3.9 million to evaluate the feasibility
 of an intramuscular (IM) route of administration using AVI-7288,
 the Company&amp;#x2019;s candidate for treatment of Marburg virus. The
 period of performance of this contract concluded in the third
 quarter of 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;&lt;u&gt;Other Agreements&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the nine month period ended September&amp;#xA0;30, 2013, Other
 Agreements includes $0.4 million in additional revenue from a
 former US government contract of the Company related to H1N1
 influenza.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;European Union SKIP-NMD Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In November 2012, the Company entered into an agreement for a
 collaborative research project partially funded by the EC Health
 Innovation. The agreement provides for reimbursement of costs of
 approximately $2.5 million for research in certain development and
 study related activities for a DMD therapeutic and is expected to
 last approximately three years.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During the nine months ended September&amp;#xA0;30, 2013, the Company
 received $1.3 million in advance payments and recognized $0.6
 million of these payments as revenue. Deferred revenue related to
 the agreement as of September&amp;#xA0;30, 2013 was $0.7 million. The
 remaining balance of deferred revenue relates to the
 Company&amp;#x2019;s sponsored research agreement with Charley&amp;#x2019;s
 Fund from prior years.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Children&amp;#x2019;s National Medical Center (CNMC)
 Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In July 2013, the Company entered into an agreement totaling $1.3
 million to provide drug product to CNMC to conduct research related
 to the Company&amp;#x2019;s DMD program. During the three and nine
 months ended September&amp;#xA0;30, 2013, the Company has recognized
 $0.7 million as revenue under the agreement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_76E79F7E-3CAD-4798-8400-C566C54AD991_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;1. ORGANIZATION AND BASIS OF PRESENTATION&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Sarepta Therapeutics, Inc. and its wholly-owned subsidiaries
 (&amp;#x201C;Sarepta&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) is a
 biopharmaceutical company focused on the discovery and development
 of unique RNA-based therapeutics for the treatment of rare and
 infectious diseases. Applying the Company&amp;#x2019;s proprietary
 platform technologies, the Company is able to target a broad range
 of diseases and disorders through distinct RNA-based mechanisms of
 action. The Company is focused on advancing the development of its
 Duchenne muscular dystrophy (DMD) drug candidates, including its
 lead product candidate, eteplirsen, for which the Company is
 currently conducting an ongoing open label extension study
 following completion of its initial Phase IIb clinical trials. The
 Company is also focused on developing therapeutics for the
 treatment of infectious diseases, including its lead infectious
 disease program aimed at the development of a drug candidate for
 the Marburg hemorrhagic fever virus for which the Company has
 historically received significant financial support from U.S.
 government research contracts.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accompanying unaudited condensed consolidated financial
 statements reflect the accounts of Sarepta and its consolidated
 subsidiaries. The accompanying unaudited condensed consolidated
 balance sheet data as of December&amp;#xA0;31, 2012 was derived from
 audited financial statements not included in this report. The
 accompanying unaudited condensed consolidated financial statements
 were prepared in conformity with accounting principles generally
 accepted in the United States of America (GAAP) and the
 rules&amp;#xA0;and regulations of the U.S. Securities and Exchange
 Commission (SEC) pertaining to interim financial statements.
 Accordingly, they do not include all of the information and
 footnotes required by GAAP for complete financial statements. The
 accompanying unaudited condensed consolidated financial statements
 should be read in conjunction with the financial statements and the
 notes thereto included in the Company&amp;#x2019;s annual report on
 Form&amp;#xA0;10-K for the year ended December&amp;#xA0;31, 2012. The
 results of operations for the interim periods presented are not
 necessarily indicative of the results to be expected for the full
 year.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Management has determined that the Company operates in one segment:
 the development of pharmaceutical products on its own behalf or in
 collaboration with others.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Since its inception in 1980, the Company has incurred losses of
 $534.4 million, substantially all of which resulted from
 expenditures related to research and development, general and
 administrative charges and losses on change in warrant valuation
 partially offset by revenue generated from research contracts with
 and grants primarily from the U.S. Department of Defense (DoD). As
 of September&amp;#xA0;30, 2013, the Company has completed all of its
 contracts with the DoD except for the July 2010 contract for the
 development of therapeutics against the Marburg virus. The period
 of performance for the Company&amp;#x2019;s August 2012 contract with
 the DoD related to the Marburg virus concluded in the third quarter
 of 2013. In November 2012, the Company entered into an agreement
 with the European Commission (EC) Health Innovation for development
 and study related activities for a DMD therapeutic. The Company has
 not generated any material revenue from product sales to date, and
 there can be no assurance that revenue from product sales will be
 achieved. Moreover, even if the Company does achieve revenue from
 product sales, the Company is likely to continue to incur operating
 losses in the near term.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of September&amp;#xA0;30, 2013, the Company had $281.4&amp;#xA0;million
 of cash, cash equivalents and invested cash, comprised of
 $273.6&amp;#xA0;million of cash and cash equivalents and
 $7.8&amp;#xA0;million of restricted investments. The Company believes
 its cash, cash equivalents and invested cash is sufficient to fund
 the Company&amp;#x2019;s current operational plan for the next twelve
 months. Should the Company&amp;#x2019;s funding from the DoD cease or be
 delayed, the Company would likely curtail certain of its infectious
 disease research and development efforts unless additional funding
 was obtained. The Company is also likely to pursue additional cash
 resources through public or private financings, seeking additional
 government contracts, and from establishing collaborations or
 licensing its technology to other companies.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Estimates and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the financial
 statements and the reported amounts of revenue and expenses during
 the reporting period. Actual results could differ from those
 estimates.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Commitments and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In the normal course of business, the Company may from time to time
 be named as a party to various legal claims, actions and
 complaints, including matters involving employment, intellectual
 property, and effects from the use
 of&amp;#xA0;therapeutics&amp;#xA0;utilizing its technology, professional
 services or others. Although there are significant inherent
 uncertainties in connection with these legal matters, management
 believes the resolution of current matters will not have a material
 impact on the Company&amp;#x2019;s financial position, results of
 operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the Company issued two letters of credit totaling
 $7.3 million to a contract manufacturing vendor in connection with
 certain manufacturing agreements. The obligations secured by the
 letters of credit are fulfilled upon payment for certain minimum
 volume commitments that the Company expects to occur within the
 next twelve months. To meet the requirement of the letters of
 credit, the Company purchased $7.3 million in certificates of
 deposit with April 2014 maturity dates in February 2013. The
 Company has recorded this $7.3 million as restricted investments in
 the condensed consolidated balance sheet as of September&amp;#xA0;30,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In April 2013, the Company and the University of Western Australia
 (UWA) entered into an agreement under which an existing exclusive
 license agreement between the Company and UWA was amended and
 restated. Under the terms of this agreement, UWA granted the
 Company an exclusive license to certain UWA intellectual property
 rights in exchange for up to $7.1 million in upfront and
 development milestone payments. In April 2013, the Company
 recognized expense of $1.0 million relating to certain upfront
 payments required under the agreement within research and
 development in the condensed consolidated statement of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June 2013, the Company entered into a lease agreement for its
 Cambridge, Massachusetts location. The agreement calls for a
 security deposit in the form of a letter of credit totaling $0.6
 million. The Company purchased a certificate of deposit to meet the
 requirement. The initial term of the lease agreement is for seven
 years with an average base rent of approximately $2.4 million per
 year. At September&amp;#xA0;30, 2013, the Company recorded construction
 in progress related to the lease totaling $4.7 million in property
 and equipment in the condensed consolidated balance sheet of which
 $3.7 million was paid by the landlord as part of a tenant
 improvement allowance which is recorded in other long-term
 liabilities.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_22">32588000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_0790E867-83FE-422C-8AD1-1E26F89AC70E_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;(in&amp;#xA0;thousands,&amp;#xA0;except&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;per&amp;#xA0;share&amp;#xA0;amounts)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands,&amp;#xA0;except&lt;br /&gt;
 per&amp;#xA0;share&amp;#xA0;amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(42,030&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(103,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(59,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of shares of common stock and common stock
 equivalents&amp;#xA0;outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of common shares outstanding for computing
 basic earnings per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,943&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Dilutive effect of outstanding warrants and stock awards after
 application of the treasury stock method*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of common shares outstanding for computing
 diluted earnings per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,943&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss per share &amp;#x2014; basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss per share &amp;#x2014; diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Warrants, stock options, restricted
 stock units (RSUs) and stock appreciation rights (SARs) to purchase
 approximately 5,293,145 and 7,371,471 shares of common stock were
 excluded from the net loss per share calculation for the three and
 nine months ended September&amp;#xA0;30, 2013 and 2012, respectively,
 as their effect would have been anti-dilutive.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_A361D817-DBEF-45B7-AF19-8F79AE51B05E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;6. EQUITY FINANCINGS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In January 2013, the Company sold approximately 87,000 shares of
 common stock through its At-The-Market (ATM) offering that
 originally commenced in September 2012 (the 2012 ATM). The sales in
 January 2013 generated $2.1 million in net proceeds and fully
 exhausted the sales of common stock available under the 2012 ATM
 sales agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On July&amp;#xA0;3, 2013, the Company entered into a second ATM
 offering (the 2013 ATM) allowing the Company to sell, at its
 option, up to an aggregate of $125 million of shares of common
 stock at market prices. Through September&amp;#xA0;30, 2013, the
 Company has sold approximately 3.4&amp;#xA0;million shares under the
 2013 ATM generating $123.0 million in net proceeds and has
 completed the sales of common stock available under the
 arrangement.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_A8821A89-C5C3-4A6B-B197-D14DFBEB1647_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;11. RECENT ACCOUNTING PRONOUNCEMENTS&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the Financial Accounting Standards Board (FASB)
 issued new guidance which requires disclosure of significant
 amounts reclassified out of accumulated other comprehensive income
 by component and their corresponding effect on the respective line
 items of net income. This guidance was adopted by the Company in
 fiscal year 2013. The adoption of this guidance did not have an
 impact on the Company&amp;#x2019;s unaudited condensed consolidated
 financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In July 2013, the FASB issued new guidance which amends the
 guidance related to the presentation of unrecognized tax benefits
 and allows for the reduction of a deferred tax asset for a NOL
 carryforward whenever the NOL or tax credit carryforward would be
 available to reduce the additional taxable income or tax due if the
 tax position is disallowed. The new guidance is effective for
 annual and interim periods for fiscal years beginning after
 December&amp;#xA0;15, 2013, and early adoption is permitted. Since the
 guidance relates only to the presentation of unrecognized tax
 benefits, the Company does not expect its adoption in January 2014
 will have a material effect on its financial position, results of
 operations or cash flows.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_22536589-8168-47BF-8EC7-008622B7580E_3_0">23.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_94288678-1DB0-4AE2-AA41-5B7380EE08BA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;10. RESTRUCTURING&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In November 2012, the Company notified 21 employees based in
 Bothell, Washington that they would be terminated as part of the
 relocation of the Company&amp;#x2019;s corporate headquarters to
 Cambridge, Massachusetts. The employees were given various
 incentives to remain through a transition period which is expected
 to be completed in 2013. For the nine months ended
 September&amp;#xA0;30, 2013, the Company recorded restructuring charges
 of $0.4 million to research and development expense and $0.3
 million to general and administrative expense. All transition costs
 are expected to be paid in 2013.&lt;/p&gt;
 &lt;p style="PAGE-BREAK-BEFORE: always; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"&gt;
 &lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Changes in the liability and the balance related to the
 restructuring plan are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="18%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ending&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restructuring charges&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(821&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_14">-46873000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_00E1D4B1-AE9D-4337-A304-6F9580D9DEA7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Commitments and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In the normal course of business, the Company may from time to time
 be named as a party to various legal claims, actions and
 complaints, including matters involving employment, intellectual
 property, and effects from the use
 of&amp;#xA0;therapeutics&amp;#xA0;utilizing its technology, professional
 services or others. Although there are significant inherent
 uncertainties in connection with these legal matters, management
 believes the resolution of current matters will not have a material
 impact on the Company&amp;#x2019;s financial position, results of
 operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In February 2013, the Company issued two letters of credit totaling
 $7.3 million to a contract manufacturing vendor in connection with
 certain manufacturing agreements. The obligations secured by the
 letters of credit are fulfilled upon payment for certain minimum
 volume commitments that the Company expects to occur within the
 next twelve months. To meet the requirement of the letters of
 credit, the Company purchased $7.3 million in certificates of
 deposit with April 2014 maturity dates in February 2013. The
 Company has recorded this $7.3 million as restricted investments in
 the condensed consolidated balance sheet as of September&amp;#xA0;30,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In April 2013, the Company and the University of Western Australia
 (UWA) entered into an agreement under which an existing exclusive
 license agreement between the Company and UWA was amended and
 restated. Under the terms of this agreement, UWA granted the
 Company an exclusive license to certain UWA intellectual property
 rights in exchange for up to $7.1 million in upfront and
 development milestone payments. In April 2013, the Company
 recognized expense of $1.0 million relating to certain upfront
 payments required under the agreement within research and
 development in the condensed consolidated statement of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June 2013, the Company entered into a lease agreement for its
 Cambridge, Massachusetts location. The agreement calls for a
 security deposit in the form of a letter of credit totaling $0.6
 million. The Company purchased a certificate of deposit to meet the
 requirement. The initial term of the lease agreement is for seven
 years with an average base rent of approximately $2.4 million per
 year. At September&amp;#xA0;30, 2013, the Company recorded construction
 in progress related to the lease totaling $4.7 million in property
 and equipment in the condensed consolidated balance sheet of which
 $3.7 million was paid by the landlord as part of a tenant
 improvement allowance which is recorded in other long-term
 liabilities.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_69029785-E5CA-4A10-A7E0-F1F0B6D765F5_2001_3">P8Y6M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_F9E182C1-6677-4175-A3B0-4AF2FE7C89E2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;2. NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic net loss per share is computed by dividing net loss by the
 weighted-average number of common shares outstanding. Diluted net
 loss per share is computed by dividing net loss by the
 weighted-average number of common shares and dilutive common stock
 equivalent shares outstanding.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;(in&amp;#xA0;thousands,&amp;#xA0;except&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;per&amp;#xA0;share&amp;#xA0;amounts)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands,&amp;#xA0;except&lt;br /&gt;
 per&amp;#xA0;share&amp;#xA0;amounts)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(42,030&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(103,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(59,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of shares of common stock and common stock
 equivalents&amp;#xA0;outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of common shares outstanding for computing
 basic earnings per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,943&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Dilutive effect of outstanding warrants and stock awards after
 application of the treasury stock method*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Weighted-average number of common shares outstanding for computing
 diluted earnings per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,943&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss per share &amp;#x2014; basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net loss per share &amp;#x2014; diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Warrants, stock options, restricted
 stock units (RSUs) and stock appreciation rights (SARs) to purchase
 approximately 5,293,145 and 7,371,471 shares of common stock were
 excluded from the net loss per share calculation for the three and
 nine months ended September&amp;#xA0;30, 2013 and 2012, respectively,
 as their effect would have been anti-dilutive.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_5001_4">196012</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_5001_5">11.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_0E2CB150-7946-4F17-968C-2C82DEE3E63A_3_0">5293145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_DD4BDCA5-B3D0-4B24-A804-028A38DBCCF1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of the stock-based compensation expense, including stock
 options, RSAs, RSUs, SARs, and ESPP rights recognized in the
 condensed consolidated statements of operations and comprehensive
 income (loss) is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="53%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine months Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;421&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_7611EBFD-9B6A-40BA-8A46-85575A63B5CD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Estimates and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and the disclosure
 of contingent assets and liabilities at the date of the financial
 statements and the reported amounts of revenue and expenses during
 the reporting period. Actual results could differ from those
 estimates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_5DDF2488-20D8-4AC4-88AF-B681313D830C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair values of stock options granted during the periods
 presented were measured on the date of grant using the
 Black-Scholes-Merton option-pricing model, with the following
 assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;and&amp;#xA0;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.7%&amp;#xA0;-&amp;#xA0;1.4%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 0.6%&amp;#xA0;-&amp;#xA0;1.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 4.9-5.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.1-5.3&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;80.0%&amp;#xA0;-&amp;#xA0;88.9.%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79.7%&amp;#xA0;-&amp;#xA0;94.8%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;For the three and nine months ended
 September&amp;#xA0;30, 2013, expected volatility was estimated using a
 blend of calculated volatility of the Company&amp;#x2019;s common stock
 over a historical period and implied volatility in exchange-traded
 options associated with the Company&amp;#x2019;s common stock. Prior to
 January&amp;#xA0;1, 2013, expected volatility was estimated using
 calculated volatility of the Company&amp;#x2019;s common stock over a
 historical period commensurate with the expected term of the
 option.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_C973109C-2A12-4D1B-8373-5E13B1149C61_5001_4">8.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_1BFB97B3-B201-4AE5-BDAC-B034587793DB_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;12. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company evaluated events and transactions after the date of the
 balance sheet data but prior to the issuance of the financial
 statements for potential recognition or disclosures in its
 financial statements. The Company did not identify any material
 subsequent events requiring adjustment or disclosure.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_5FFCF34E-A4E1-48E9-B818-81F19416555A_2_1">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_21">32588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_6A65FC52-D35E-4FE2-85FE-4E40610BAA0B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;9. INCOME TAXES&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At December&amp;#xA0;31, 2012, the Company had net deferred tax assets
 of approximately $114.1 million. The net deferred tax assets are
 primarily composed of U.S. federal and state tax net operating loss
 (NOL) carryforwards, U.S. federal and state research and
 development credit carryforwards and share-based compensation
 expense. Due to uncertainties surrounding the Company&amp;#x2019;s
 ability to generate future taxable income to realize these assets,
 a full valuation allowance has been established to offset its net
 deferred tax asset. Additionally, the Internal Revenue Code
 rules&amp;#xA0;could limit the future use of its NOL and research and
 development credit carryforwards to offset future taxable income
 based on ownership changes and the value of the Company&amp;#x2019;s
 stock.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_BAA8492E-6F0E-4DEA-BF79-96E7B12B8BD7_5001_5">239072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_69029785-E5CA-4A10-A7E0-F1F0B6D765F5_2001_4">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_AE363DFC-CAF3-4F41-8722-809AF7E92FA4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;8. STOCK COMPENSATION&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s equity incentive plans allow for the granting
 of a variety of stock awards. To date, the Company has granted
 stock options, restricted stock awards, RSUs and SARs. During the
 nine months ended September&amp;#xA0;30, 2013 there were no grants,
 exercises or cancelations of SARs.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Stock-based compensation costs are based on the fair value
 calculated utilizing the Black-Scholes-Merton option pricing model
 on the date of grant. The fair value of stock awards, with
 consideration given to estimated forfeitures, is recognized as
 compensation expense on a straight-line basis over the vesting
 period of the grants.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June 2013, the Company&amp;#x2019;s stockholders approved an
 additional 3.6&amp;#xA0;million shares of common stock available for
 grants under the Amended and Restated 2011 Equity Incentive Plan
 (the 2011 Plan) and stockholders approved the 2013 Employee Stock
 Purchase Plan (ESPP) with 250,000 shares of common stock available
 to be issued. As of September&amp;#xA0;30, 2013, 2,950,714 shares of
 common stock remain available for future grants under the 2011 Plan
 and 250,000 shares are available to be issued under the ESPP.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In general, stock options granted prior to December&amp;#xA0;31, 2010
 vest over a three year period, with one-third of the underlying
 shares vesting on each anniversary of grant, and have a ten year
 term. Beginning in January 2011, stock options granted generally
 vest over a four year period, with one-fourth of the underlying
 shares vesting after one year and the remaining underlying shares
 vesting pro-ratably on a monthly basis thereafter, such that the
 underlying shares will be fully vested after four years.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June 2013, the Company granted 459,500 stock options with
 performance-based vesting criteria. The performance criteria are
 based upon the achievement of certain clinical and regulatory
 milestones. As of September&amp;#xA0;30, 2013, the achievement of these
 performance criteria is not probable and accordingly the Company
 has not recognized any expense related to these options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of the Company&amp;#x2019;s stock option activity with respect
 to the nine months ended September&amp;#xA0;30, 2013 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.15pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,522,522&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,063,396&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(196,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(239,072&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,150,834&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23.37&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;99,056,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Vested at September&amp;#xA0;30, 2013 and expected to vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,395,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,063,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Exercisable at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;891,157&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,748,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The weighted-average fair value per share of stock-based awards
 granted to employees during the three months ended
 September&amp;#xA0;30, 2013 and 2012 was $26.92 and $7.09,
 respectively, and during the nine months ended September&amp;#xA0;30,
 2013 and 2012 was $23.25 and $6.52, respectively. During the nine
 months ended September&amp;#xA0;30, 2013 and 2012, the total intrinsic
 value of stock options exercised was $5.1&amp;#xA0;million and
 $1.0&amp;#xA0;million, respectively. During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the total grant date fair value
 of stock options that vested was $3.0&amp;#xA0;million and
 $3.2&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair values of stock options granted during the periods
 presented were measured on the date of grant using the
 Black-Scholes-Merton option-pricing model, with the following
 assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;and&amp;#xA0;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.7%&amp;#xA0;-&amp;#xA0;1.4%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 0.6%&amp;#xA0;-&amp;#xA0;1.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 4.9-5.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 5.1-5.3&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;80.0%&amp;#xA0;-&amp;#xA0;88.9.%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;79.7%&amp;#xA0;-&amp;#xA0;94.8%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;For the three and nine months ended
 September&amp;#xA0;30, 2013, expected volatility was estimated using a
 blend of calculated volatility of the Company&amp;#x2019;s common stock
 over a historical period and implied volatility in exchange-traded
 options associated with the Company&amp;#x2019;s common stock. Prior to
 January&amp;#xA0;1, 2013, expected volatility was estimated using
 calculated volatility of the Company&amp;#x2019;s common stock over a
 historical period commensurate with the expected term of the
 option.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Stock Awards (RSA)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June 2013, the Company granted 6,000 shares of RSAs to members
 of its board of directors. These shares vest on the first
 anniversary of the grant and have a grant date fair value of $34.92
 per share. The weighted-average grant-date fair value of RSAs is
 based on the market price of the Company&amp;#x2019;s common stock on
 the date of grant. The following table sets forth RSA activity for
 the period shown:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value per Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Awards, beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Awards, end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Stock Units (RSU)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In April 2012, the Company granted 32,377 shares of RSUs to
 employees in lieu of cash for a portion of the 2012 bonus. In
 addition, in August 2012, 7,500 RSUs were granted to an officer of
 the Company. The remaining RSUs at September&amp;#xA0;30, 2013 will
 vest by April 2014. The following table sets forth RSU activity for
 the period shown:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&amp;#xA0;per&amp;#xA0;Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Units, beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,260&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Units, end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan (ESPP)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Company&amp;#x2019;s ESPP, participating employees purchase
 common stock through payroll deductions. The purchase price is
 equal to 85% of the lower of the closing price of the
 Company&amp;#x2019;s common stock on the first business day and the last
 business day of the relevant plan period. The initial 26-month
 award period will end on August&amp;#xA0;31, 2015. Each subsequent
 offering period will begin on March&amp;#xA0;1 or September&amp;#xA0;1.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the three and nine months ended September&amp;#xA0;30, 2013, the
 fair value of stock purchase rights ranges from $16.12 to $24.65
 per share on 59,563 shares estimated to be purchased during the
 initial award period. The fair value was estimated using the
 Black-Scholes-Merton option-pricing model. The Company used a
 weighted-average stock-price volatility ranging from 84% to 98%,
 expected option life assumption from 0.7 to 2.2 years and a
 risk-free interest rate from 0.1% to 0.4%. The Company recorded
 $0.3 million of stock-based compensation expense for the three and
 nine months ended September&amp;#xA0;30, 2013 related to the ESPP.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of the stock-based compensation expense, including stock
 options, RSAs, RSUs, SARs, and ESPP rights recognized in the
 condensed consolidated statements of operations and comprehensive
 income (loss) is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="53%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine months Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;783&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;421&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,487&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,476&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of September&amp;#xA0;30, 2013, there was $49.6&amp;#xA0;million of
 unrecognized compensation cost related to non-vested share-based
 compensation arrangements outstanding including stock options,
 RSAs, RSUs, SARs and ESPP rights. These costs are expected to be
 recognized over a weighted-average period of 3.2 years.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_D22ABBFD-15B3-4E64-A31B-D8769FE7DEAB_1_0">&lt;div&gt;
 &lt;p&gt;The following table sets forth RSA activity for the period
 shown:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value per Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Awards, beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Awards, end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" id="id_2548261_14E29CE5-E891-4187-ACF9-6F878339AD89_1_0">&lt;div&gt;
 &lt;p&gt;The following table sets forth RSU activity for the period
 shown:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant&amp;#xA0;Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&amp;#xA0;per&amp;#xA0;Share&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Units, beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;38,260&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Canceled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Restricted Stock Units, end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="Segment" decimals="INF" id="id_2548261_397C9549-C768-402C-960C-017BEF62BAB3_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C269DCE9-4D69-402D-BA05-0D774575A8EF_1_3">821000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_17">1762000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_16">7807000</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_C7DEF05D-59F3-41EE-9D75-D5162EC8A8A4_1_1">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_4">-460000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_25">67000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:InterestPaid contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_33">123000</us-gaap:InterestPaid>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_7">281000</us-gaap:InvestmentIncomeNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_12">520000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_18">-103165000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_0">11593000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_5">-57435000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_18">1281000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsForTenantImprovements contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_37">3692000</us-gaap:PaymentsForTenantImprovements>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_11">-45730000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_12">-103165000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_17" />
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_26">-178000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_3">21195000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_27">143706000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_8">7476000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_28">85983000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_13">1867000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_C7DEF05D-59F3-41EE-9D75-D5162EC8A8A4_1_0">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_B4E5FC05-CC7A-4F1B-AF01-BF98CBF856DF_2_1">123000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2548261_00CED321-5D08-4346-BF56-B4460AA4BF2F_1_0">0</us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_3">998000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:RestructuringCharges contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C269DCE9-4D69-402D-BA05-0D774575A8EF_1_2">726000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_3_2">7476000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_22">-10850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_1_2">17100000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_2">47833000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_3_8">46011000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_24">143951000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_1_36">75210000</srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <srpt:ClassOfWarrantNumberOfSecuritiesCalledByWarrants contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1_7">959283</srpt:ClassOfWarrantNumberOfSecuritiesCalledByWarrants>
  <srpt:ClassOfWarrantOrRightWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="iso4217_USD_per_Unit" decimals="2" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_1_1">7.91</srpt:ClassOfWarrantOrRightWeightedAverageExercisePrice>
  <srpt:ClassOfWarrantOrRightExercised contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_1_0">2168335</srpt:ClassOfWarrantOrRightExercised>
  <srpt:WeightedAverageRemainingContractualLifeWarrants contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_709283x760806" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_2_5">P10M24D</srpt:WeightedAverageRemainingContractualLifeWarrants>
  <srpt:WeightedAverageRemainingContractualLifeWarrants contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_709283x803399" id="id_2548261_9C8A3158-4B83-49A0-AAD3-84A509D52C38_1_5">P9M18D</srpt:WeightedAverageRemainingContractualLifeWarrants>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_709650x715581" id="id_2548261_C9858E74-1A2C-4B39-B0A9-2B9FA0D4DC68_1_0">&lt;div&gt;
 &lt;p&gt;The following reflects the weighted-average assumptions for each
 of the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.2%-0.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.8-0.9&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.1-1.6&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility (1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;67.8%-72.7&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;139.2%-164.1&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Shares underlying warrants classified as liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;959,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,127,618&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Market value of stock at beginning of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Market value of stock at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47.23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25.80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1px solid; LINE-HEIGHT: 8pt; MARGIN-TOP: 0pt; WIDTH: 10%; MARGIN-BOTTOM: 2pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;For the three and nine months ended
 September&amp;#xA0;30, 2013, expected volatility was estimated using a
 blend of calculated volatility of the Company&amp;#x2019;s common stock
 over a historical period and implied volatility in exchange-traded
 options associated with the Company&amp;#x2019;s common stock. Prior to
 January&amp;#xA0;1, 2013, expected volatility was estimated using
 calculated volatility of the Company&amp;#x2019;s common stock over a
 historical period commensurate with the expected term of the
 option.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C239D094-8F70-4C47-BE2F-423175BE7831_1002_2">75210000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1002_0">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1002_6">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1002_4">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_5">0.678</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_0">0.001</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_3">P9M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169_713115x715677" unitRef="pure" decimals="3" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_1002_6">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169_713115x715677" unitRef="pure" decimals="2" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_1002_4">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169_713115x715677" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_1002_8">P8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2002_1">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2002_7">0.889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2002_5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2001_6">0.727</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2001_4">P10M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112_713115x715677" unitRef="pure" decimals="3" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_2002_7">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112_713115x715677" unitRef="pure" decimals="2" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_2002_5">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112_713115x715677" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_2002_9">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <srpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardWeightedAverageFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112_713115x715677" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_2002_3">24.65</srpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardWeightedAverageFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711528x805788_713879x837386" unitRef="pure" decimals="4" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_1001_5">0.0250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711528x834993_713879x837386" unitRef="pure" decimals="4" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_2001_4">0.2500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x803136" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_1003_2">599000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x804211" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_2003_0">7134000</us-gaap:ContractsRevenue>
  <srpt:NumberOfSegments contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x804211" unitRef="Segment" decimals="INF" id="id_2548261_7202B35D-4EBE-4FF5-9CB5-7B1B836038B0_1001_0">4</srpt:NumberOfSegments>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x818698" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_3003_1">2759000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x818699" unitRef="iso4217_USD" decimals="-3" id="id_2548261_1698C069-BD94-42E8-AF31-040BA5A38074_1001_0">427000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x867305" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E875EE3C-1729-4E5C-9AC4-C2B9D64E7945_1003_1">674000</us-gaap:ContractsRevenue>
  <us-gaap:RestructuringCharges contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x707836" unitRef="iso4217_USD" decimals="-5" id="id_2548261_2FC61A4F-8ADB-422F-9351-5261D6BDED02_1001_1">300000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_1003_1">5067000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestructuringCharges contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x713040" unitRef="iso4217_USD" decimals="-5" id="id_2548261_2FC61A4F-8ADB-422F-9351-5261D6BDED02_2001_0">400000</us-gaap:RestructuringCharges>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_2003_0">2409000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715677" unitRef="shares" decimals="INF" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_3002_1">59563</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715677" unitRef="iso4217_USD" decimals="-5" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_3002_10">300000</us-gaap:ShareBasedCompensation>
  <srpt:CommonStockClosingPricePercentage contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715677" unitRef="pure" decimals="2" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_3002_0">0.85</srpt:CommonStockClosingPricePercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_412297E6-BA2F-402C-ACDD-C9368B316898_1001_3">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="shares" decimals="INF" id="id_2548261_6583C58E-E609-4835-A63B-0E0436042718_1001_2">24858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_412297E6-BA2F-402C-ACDD-C9368B316898_1001_2">6.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_2548261_412297E6-BA2F-402C-ACDD-C9368B316898_1001_1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="shares" decimals="INF" id="id_2548261_6583C58E-E609-4835-A63B-0E0436042718_1001_3">374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834" unitRef="shares" xsi:nil="true" id="id_2548261_6583C58E-E609-4835-A63B-0E0436042718_1001_1" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="0" id="id_2548261_0226406A-AF0D-4E45-BD54-BB8592E5FC44_1001_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_683B19F3-31F3-4366-AF72-D944C2A1E995_1001_2">4998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_0226406A-AF0D-4E45-BD54-BB8592E5FC44_1001_2">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_0226406A-AF0D-4E45-BD54-BB8592E5FC44_1001_1">34.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_683B19F3-31F3-4366-AF72-D944C2A1E995_1001_1">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x777319" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_3001_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x777319" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_3001_0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x777319" unitRef="pure" decimals="4" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_3001_1">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x837386" id="id_2548261_337554BB-FF04-4249-85B8-D146AAACA7CE_4001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x857854" unitRef="shares" decimals="-5" id="id_2548261_4D373CC7-FBB0-4422-9EEE-1B317DAD0299_1002_3">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_714938x715452" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1003_6">P7Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <srpt:UpfrontFeeRecognizedAsResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1003_17">1000000</srpt:UpfrontFeeRecognizedAsResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_716644x708634" unitRef="iso4217_USD" decimals="-5" id="id_2548261_4702E91D-49E2-46EF-A6CA-DB1F9F85FE27_1001_0">1300000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="eol_PE3458----1310-Q0009_STD_273_20130930_0_716644x708634" unitRef="iso4217_USD" decimals="-5" id="id_2548261_4702E91D-49E2-46EF-A6CA-DB1F9F85FE27_1001_1">600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_19">-2.61</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_20">-2.61</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_22">22691000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_22536589-8168-47BF-8EC7-008622B7580E_4_0">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="pure" decimals="2" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_4_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_14">-22536000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2548261_0E2CB150-7946-4F17-968C-2C82DEE3E63A_4_0">7371471</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_21">22691000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_17">108000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_C7DEF05D-59F3-41EE-9D75-D5162EC8A8A4_2_1">3200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_4">-182000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_25">64000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:InterestPaid contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_33">65000</us-gaap:InterestPaid>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_7">270000</us-gaap:InvestmentIncomeNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_12">1162000</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_18">-59220000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_0">29993000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_5">-19336000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_18">614000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_11">-39884000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_12">-59220000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_3">9761000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_27">21341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_8">1840000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_28">-1917000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_13">-5420000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_C7DEF05D-59F3-41EE-9D75-D5162EC8A8A4_2_0">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_3">1090000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_4_2">1840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_22">-722000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_2_2">300000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_2">39568000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_4_8">40154000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_24">21405000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_363375A6-7F48-4AB7-BD8E-81566584848C_2_36">391000</srpt:IssuanceOfCommonStockAndWarrantsInSatisfactionOfLiabilities>
  <srpt:ClassOfWarrantOrRightWeightedAverageExercisePrice contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="iso4217_USD_per_Unit" decimals="2" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_2_1">4.08</srpt:ClassOfWarrantOrRightWeightedAverageExercisePrice>
  <srpt:ClassOfWarrantOrRightExercised contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2548261_E0D93EC1-7CFC-4C66-8248-AE2B0A8C0A9A_2_0">80014</srpt:ClassOfWarrantOrRightExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1004_0">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1004_6">0.797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x711169" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1004_4">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2004_1">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2004_7">0.948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x716112" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2004_5">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x804211" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_2004_0">29844000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x818698" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_3004_1">50000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x818699" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_4004_4">99000</us-gaap:ContractsRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_1004_1">1057000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_274_20120930_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_2004_0">783000</us-gaap:AllocatedShareBasedCompensationExpense>
  <srpt:PurchasesOfCertificatesOfDeposit contextRef="eol_PE3458----1310-Q0009_STD_28_20130228_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1_1">7300000</srpt:PurchasesOfCertificatesOfDeposit>
  <srpt:NumberOfLetterOfCredit contextRef="eol_PE3458----1310-Q0009_STD_28_20130228_0" unitRef="CreditFacility" decimals="INF" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1_4">2</srpt:NumberOfLetterOfCredit>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE3458----1310-Q0009_STD_29_20120829_0_711809x768572" unitRef="iso4217_USD" decimals="-5" id="id_2548261_0ED75720-41F0-4FA5-8B41-DA46B68C6A7E_1001_0">3900000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_30_20120430_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_BAA115E0-599E-4893-8714-9A51D100C9A5_1002_0">32377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="eol_PE3458----1310-Q0009_STD_30_20121130_0" unitRef="Position" decimals="INF" id="id_2548261_8EE0806E-CA64-4F02-8FE5-60A27D5BC0CC_1_0">21</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="eol_PE3458----1310-Q0009_STD_30_20121130_0_716644x708634" unitRef="iso4217_USD" decimals="-5" id="id_2548261_2FFE2848-B698-44AF-8ED3-708E853614F0_1001_0">2500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
  <srpt:PotentialFundingPeriod contextRef="eol_PE3458----1310-Q0009_STD_30_20121130_0_716644x708634" id="id_2548261_2FFE2848-B698-44AF-8ED3-708E853614F0_1001_1">P3Y</srpt:PotentialFundingPeriod>
  <srpt:UpfrontAndDevelopmentMilestonePayments contextRef="eol_PE3458----1310-Q0009_STD_30_20130430_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_4_14">7100000</srpt:UpfrontAndDevelopmentMilestonePayments>
  <srpt:UpfrontFeeRecognizedAsResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_30_20130430_0_714938x715452" unitRef="iso4217_USD" decimals="-5" id="id_2548261_70F7829A-BB40-432E-9245-0A6C5D4FA0CD_1004_17">1000000</srpt:UpfrontFeeRecognizedAsResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_30_20130630_0_713115x707592" unitRef="shares" decimals="INF" id="id_2548261_25C212BD-ABFB-4CE2-ABB1-2F568FFECA1F_1001_0">459500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_30_20130630_0_713115x716908" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BAA115E0-599E-4893-8714-9A51D100C9A5_1001_1">34.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_30_20130630_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_BAA115E0-599E-4893-8714-9A51D100C9A5_1001_0">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE3458----1310-Q0009_STD_30_20130703_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_B4E5FC05-CC7A-4F1B-AF01-BF98CBF856DF_1_1">125000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE3458----1310-Q0009_STD_31_20130131_0" unitRef="shares" decimals="INF" id="id_2548261_9945A045-5CBB-473B-B11E-2D0580C828A0_1_0">87000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE3458----1310-Q0009_STD_31_20130131_0" unitRef="iso4217_USD" decimals="-5" id="id_2548261_9945A045-5CBB-473B-B11E-2D0580C828A0_1_1">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="eol_PE3458----1310-Q0009_STD_31_20130731_0_711809x867305" unitRef="iso4217_USD" decimals="-5" id="id_2548261_E875EE3C-1729-4E5C-9AC4-C2B9D64E7945_1001_0">1300000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE3458----1310-Q0009_STD_31_20130831_0_713115x716908" unitRef="shares" decimals="INF" id="id_2548261_BAA115E0-599E-4893-8714-9A51D100C9A5_1003_0">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0" unitRef="pure" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2_2">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <srpt:ClassOfWarrantNumberOfSecuritiesCalledByWarrants contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2_7">3127618</srpt:ClassOfWarrantNumberOfSecuritiesCalledByWarrants>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_5">1.392</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_0">0.002</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x711169" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_3">P1Y1M6D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_6">1.641</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_1">0.003</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x716112" id="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_4">P1Y7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_19">-2.17</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_20">-2.17</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_22">22824000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_22536589-8168-47BF-8EC7-008622B7580E_2_0">7.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="pure" decimals="2" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_3_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_2548261_0E2CB150-7946-4F17-968C-2C82DEE3E63A_2_0">7371471</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_21">22824000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_7">67000</us-gaap:InvestmentIncomeNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_18">-49554000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_0">7574000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_5">-6905000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_11">-42649000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_12">-49554000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_3">3565000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_2_2">692000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_2">10914000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_2_8">42716000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1003_0">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1003_6">0.797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x711169" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1003_4">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2003_1">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2003_7">0.948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x716112" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2003_5">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x804211" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_2002_0">7511000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x818698" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_3002_1">50000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x818699" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_4002_4">13000</us-gaap:ContractsRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_1002_1">421000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20120930_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_2002_0">271000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_19">-1.24</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_20">-1.24</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_22">33943000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_22536589-8168-47BF-8EC7-008622B7580E_1_0">26.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="pure" decimals="2" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_2548261_0E2CB150-7946-4F17-968C-2C82DEE3E63A_1_0">5293145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="shares" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_21">33943000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:InvestmentIncomeNet contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_7">63000</us-gaap:InvestmentIncomeNet>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_18">-42030000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_0">4168000</us-gaap:ContractsRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_5">-24933000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_11">-17097000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_12">-42030000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_17" />
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_3">8014000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_1_2">3487000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_2">21087000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_2548261_BD34432C-B674-43B4-8489-00C7412C518B_1_8">17160000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_709650x715581" unitRef="iso4217_USD" decimals="-3" id="id_2548261_C239D094-8F70-4C47-BE2F-423175BE7831_1001_2">60282000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1001_0">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1001_6">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_1001_4">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <srpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardWeightedAverageFairValue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169_713115x715677" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_1001_2">16.12</srpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBasedAwardWeightedAverageFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2001_1">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x716112" unitRef="pure" decimals="3" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2001_7">0.889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x716112" id="id_2548261_79395492-72A6-45DC-8707-18C42601C427_2001_5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x803136" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_1001_2">536000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x804211" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_2001_0">2444000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x818698" unitRef="iso4217_USD" decimals="-3" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_3001_1">514000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x818699" unitRef="iso4217_USD" xsi:nil="true" id="id_2548261_94350A01-238B-4D36-B3DA-4062FDA3C59A_4001_4" />
  <us-gaap:ContractsRevenue contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x867305" unitRef="iso4217_USD" decimals="-3" id="id_2548261_E875EE3C-1729-4E5C-9AC4-C2B9D64E7945_1002_1">674000</us-gaap:ContractsRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_1001_1">2332000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_2548261_CEC8D299-438F-4497-BAB6-D924EFB034B0_2001_0">1155000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE3458----1310-Q0009_STD_92_20130930_0_713115x715677" unitRef="iso4217_USD" decimals="-5" id="id_2548261_789B0A45-2EB7-4BE9-BC9B-CD6480F684D0_3001_10">300000</us-gaap:ShareBasedCompensation>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x867305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:ChildrenNationalMedicalCenterAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x818699">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x818698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:IntramuscularAugustTwoThousandTwelveAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x804211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:EbolaAndMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711809x803136">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:SkipNmdAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x818699">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x818698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:IntramuscularAugustTwoThousandTwelveAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_711809x804211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:EbolaAndMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_366_20121231_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_31_20130831_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-08-01</startDate>
      <endDate>2013-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_31_20130731_0_711809x867305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:ChildrenNationalMedicalCenterAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_31_20130131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20130703_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-06-04</startDate>
      <endDate>2013-07-03</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20130630_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20130630_0_713115x707592">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20130430_0_714938x715452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20130430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20121130_0_716644x708634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-11-01</startDate>
      <endDate>2012-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20121130_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2012-11-01</startDate>
      <endDate>2012-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_30_20120430_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_29_20120829_0_711809x768572">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:AugustTwoThousandTwelveAgreementIntramuscularMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-29</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_28_20130228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-02-01</startDate>
      <endDate>2013-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x818699">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x818698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:IntramuscularAugustTwoThousandTwelveAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_711809x804211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:EbolaAndMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_716644x708634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_714938x715452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x857854">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:AmendedAndRestatedTwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x837386">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandElevenBeginningInJuneTwoThousandElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713879x777319">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandTwoToDecemberTwoThousandTenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715834">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x867305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:ChildrenNationalMedicalCenterAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x818699">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x818698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:IntramuscularAugustTwoThousandTwelveAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x804211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:EbolaAndMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711809x803136">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:SkipNmdAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711528x834993_713879x837386">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandElevenBeginningInJuneTwoThousandElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">srpt:FirstAnniversaryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711528x805788_713879x837386">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandElevenBeginningInJuneTwoThousandElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">srpt:VestingMonthAfterFirstAnniversaryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_709650x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_709283x803399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">srpt:ExercisePriceRangeOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0_709283x760806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">srpt:ExercisePriceRangeTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x715869">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis">us-gaap:BuildingMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>1980-07-22</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_12124_20130930_0_713008x709525">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:NoncashOrPartNoncashAcquisitionsByUniqueDescriptionAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>1980-07-22</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_12124_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <startDate>1980-07-22</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_713115x715834">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_716644x708634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_714938x715452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_713879x837386">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandElevenBeginningInJuneTwoThousandElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x716908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715834">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715677_713879x837386">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srpt:StockIncentivePlanTwoThousandElevenBeginningInJuneTwoThousandElevenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_713115x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715990x708500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798_715990x708500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855_715990x708500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740_715990x715868">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740_715990x708500">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_711809x828901">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:PhaseTwoThreeFourMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_711809x804211">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">srpt:EbolaAndMarburgMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x803399">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">srpt:ExercisePriceRangeOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0_709283x760806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">srpt:ExercisePriceRangeTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20131031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE3458----1310-Q0009_STD_0_20130228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000873303</identifier>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>srpt:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Segment">
    <measure>srpt:Segment</measure>
  </unit>
  <unit id="iso4217_USD_per_Unit">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>srpt:Unit</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="CreditFacility">
    <measure>srpt:CreditFacility</measure>
  </unit>
  <unit id="Position">
    <measure>srpt:Position</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_5" xlink:label="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_5" xlink:label="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2001_6" xlink:label="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2001_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_6" xlink:label="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1001_3" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1001_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1002_3" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1002_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1003_3" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1003_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1004_3" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1004_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3001_1" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3001_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3002_1" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3002_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3003_1" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3003_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3004_1" xlink:label="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3004_1" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_183035916" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 5 for additional information related to the determination of fair value of warrants and a reconciliation of changes in fair value.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_183035931" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For the three and nine months ended September 30, 2013, expected volatility was estimated using a blend of calculated volatility of the Company's common stock over a historical period and implied volatility in exchange-traded options associated with the Company's common stock. Prior to January 1, 2013, expected volatility was estimated using calculated volatility of the Company's common stock over a historical period commensurate with the expected term of the option.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1001_5" xlink:to="footnote_183035931" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_1002_5" xlink:to="footnote_183035931" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2001_6" xlink:to="footnote_183035931" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_394EA31F-5CA7-4013-B57C-C489A634A407_2002_6" xlink:to="footnote_183035931" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1001_3" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1002_3" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1003_3" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_1004_3" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3001_1" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3002_1" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3003_1" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_2548261_EF56CD1C-A164-401D-BDD5-FF5592D0295D_3004_1" xlink:to="footnote_183035916" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>